Natural Products for Neurodegenerative Drugs Development
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Natural Products Chemistry".
Deadline for manuscript submissions: closed (15 October 2023) | Viewed by 427
Special Issue Editor
Special Issue Information
Dear Colleagues,
Neurodegenerative diseases of the nervous system impose substantial medical and public health burdens on populations throughout the world. Neurodegenerative diseases, including chronic diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis, and acute diseases like traumatic brain injury and ischemic stroke are characterized by progressive degeneration, brain tissue damage and loss of neurons, accompanied by behavioral and cognitive dysfunctions. The prevalence and incidence of these diseases rise dramatically with age. Thereby, the number of cases is expected to increase for the foreseeable future as life spans in many countries continue to increase. Consequently, we urgently need innovative strategies and drugs to counteract these pathological disturbances.
Natural products have played a significant role in treating and preventing diseases in past years, and are continuing to serve as important leads in drug development. As secondary metabolites, natural products have been elaborated in living organisms by complex enzyme systems. It is apparent that these natural products present more ‘drug-like’ or ‘biologically friendly’ molecular features compared with synthetic compounds. The enormous structural diversity and intrinsic properties of natural products make them continue to be an important source of drug discovery. In the neurodegenerative field, natural products-derived galantamine, huperzine A and oligofructose (GV-971) have been approved for AD treatment, and butylphthalide has been used in a clinic to treat stroke.
This Special Issue is designed to gather scientific research on bioactive natural products that have the potential to treat neurodegenerative diseases. Phytochemistry of active natural products, studies on pharmacology and possible mechanisms of action of natural products, structural modification to improve drug ability, total synthesis and biosynthesis of related natural products, or any other relevant issues can be discussed. Original research articles and critical reviews can be accepted after peer review.
Prof. Dr. Zha-Jun Zhan
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- natural products
- neurodegenerative
- stroke
- Alzheimer's disease
- Parkinson
- isolation
- structural modification
- synthesis
